Back

About

About

About the ICAT team uitklapper, klik om te openen

Utrecht is at the heart of the Netherlands life science ecosystem uitklapper, klik om te openen

Top rated research institutions and innovative patient care come together in ICAT.

Origin of ICAT uitklapper, klik om te openen

In 2016, academic institutions in Utrecht, Eindhoven, Leiden, Maastricht and Leuven (Belgium) initiated RegMedXB. RegMedXB, referring to Regenerative Medicine Crossing Borders, is a collaboration of research institutions, governments, provinces, health funds and industrial partners that aim to develop therapies for chronic diseases, based on stem cells, mini-organs, tissues and smart (bio) materials. 

In 2021, a National Growth Fund application (total €56 million) was awarded to RegMedXB, with Utrecht receiving €12.7 million. This fund will help overcome the challenge of RM, as it will be used to make a pilot plant concerning RM therapies. In Utrecht we will establish one part of that: the Innovation Center for Advanced Therapies (ICAT).

Read more

ICAT will also provide the infrastructures for part of additional National Funds like Oncode-PACT and NXTGEN HIGHTECH.

What is regenerative medicine? uitklapper, klik om te openen

Regenerative medicine researches and uses the body's self-healing ability for new therapies.

In regenerative medicine, we try to help the body recover. We do this in many different ways.

Are you looking for reliable and understandable information about regenerative medicine? The Helpdesk Regenerative Medicine or HelpdeskRM is the place where you can ask your question and read answers. 

Visit the HelpdeskRM

Ask your question!

Partners uitklapper, klik om te openen

Thank you for your review!

Has this information helped you?
Please tell us why, so that we can improve our website.

This website uses cookies

This website uses cookies This website displays videos from, among others, YouTube. Such parties place cookies (third-party cookies). If you do not want these cookies, you can indicate that here. We also place cookies ourselves to improve our site.

Read more about the cookie policy

Agree No, rather not